Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07459543 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India |
| not yet recruiting |
| Phase 4 |
| 40 |
| Bristol-Myers SquibbINDUSTRY |
| 1 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07092410 | Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib(SuRage-EB) | withdrawn | Phase 4 | 0 | SRH Wald-Klinikum Gera GmbHOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT02626065 | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies(PAIR) | completed | Phase 4 | 32 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07004335 | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study | not yet recruiting | Phase 4 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06785974 | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis(SPIRAL) | not yet recruiting | Phase 4 | 140 | Erasmus Medical CenterOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06116461 | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response(NIVOPTIMIZE) | unknown | Phase 4 | 34 | Erasmus Medical CenterOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT01856023 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma(PROCLIVITY02) | terminated | Phase 4 | 29 | Clinigen, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02068196 | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.(Ipi4) | active not recruiting | Phase 4 | 150 | Oslo University HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05467137 | Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG(MelanooMSOT) | unknown | Phase 4 | 10 | University Medical Center GroningenOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT00414765 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | completed | Phase 4 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01683188 | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma(PROCLIVITY01) | terminated | Phase 4 | 53 | Clinigen, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04261179 | Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer(SENTINELSEEK) | unknown | Phase 4 | 30 | Anna CrucetaOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02451488 | Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma | completed | Phase 4 | 8 | Mayo ClinicOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01898585 | An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma | completed | Phase 4 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02685592 | Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream(LM PDT) | completed | Phase 4 | 10 | Joint Authority for Päijät-Häme Social and Health CareOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01053819 | Can We Miss Pigmented Lesions in Psoriasis Patients? | completed | Phase 4 | 6 | University of Alabama at BirminghamOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02379000 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | unknown | Phase 4 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01161888 | Effect of Topical Imiquimod on Lentigo Maligna(LIMIT-1) | completed | Phase 4 | 30 | Jerry MarsdenOTHER | 1 | Jun 20, 2012 | clinicaltrials |
| NCT00324272 | Post-Operative Drainage Following Lymph Node Dissection | completed | Phase 4 | 74 | Oxford University Hospitals NHS TrustOTHER | 0 | Aug 11, 2011 | clinicaltrials |
| NCT00075166 | Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors | completed | Phase 4 | 130 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00540930 | Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy | unknown | Phase 4 | 400 | Shields, Shields and AssociatesOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00226473 | Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma | unknown | Phase 4 | 200 | Dermatologic Cooperative Oncology GroupOTHER | 1 | Jun 21, 2006 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials